Latest Ratios: P/E Ratio -5.0x · EV/EBITDA N/A · ROE -41.3%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $288M | $847M | $199M | $198M | $529M | $199M | — | — | — |
| Enterprise Value | $267M | $826M | $162M | $176M | $497M | $59M | — | — | — |
| P/E Ratio → | -4.95 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 233.89 | — | — | — | — | — | — |
| P/B Ratio | 1.67 | 4.30 | 1.59 | 1.33 | 2.91 | 1.42 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 190.54 | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | — | — | — | — | — | — |
| Operating Margin | — | — | -6661.8% | — | — | — | — | — | — |
| Net Profit Margin | — | — | -5808.8% | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -41.3% | -41.3% | -36.1% | -25.7% | -24.4% | -91.3% | -73.9% | — | — |
| ROA | -36.9% | -36.9% | -33.2% | -23.8% | -22.2% | -79.9% | -71.7% | -73.1% | -59.2% |
| ROIC | -41.3% | -41.3% | -39.6% | -27.4% | -41.9% | -6808.4% | -946.8% | — | — |
| ROCE | -43.2% | -43.2% | -40.4% | -30.3% | -25.5% | -88.6% | -89.2% | -88.8% | -68.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.05 | 0.01 | 0.02 | 0.03 | 0.23 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.11 | -0.29 | -0.15 | -0.18 | -1.00 | -0.94 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -17.65 | -221.11 | -30.63 | -27.73 | -49.95 |
Net cash position: cash ($31M) exceeds total debt ($10M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.02 | 15.02 | 14.96 | 19.73 | 12.05 | 13.84 | 4.97 | 2.67 | 6.96 |
| Quick Ratio | 15.02 | 15.02 | 14.96 | 19.73 | 12.05 | 13.84 | 4.97 | 2.67 | 6.96 |
| Cash Ratio | 14.96 | 14.96 | 14.28 | 19.54 | 11.54 | 13.59 | 4.66 | 2.58 | 6.79 |
| Asset Turnover | — | — | 0.01 | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $158M | $137M | $127M | $105M | $63M | $56M | $52M | $5M |
Clinical trial funding dependency
Based on reported figures, CMPX trades at a price-to-book ratio of 1.67, which reflects the market's heavy discounting of the company's intangible pipeline value relative to its limited tangible asset base, as the firm lacks the commercial revenue necessary to support traditional earnings-based valuation multiples like P/E.
The negative TTM P/E of -4.95 is a direct consequence of the company's pre-revenue status and ongoing R&D investment cycle. Investors should interpret this valuation as a pure option on the success of the CTX-009 program rather than a reflection of current operational performance.
As reported in financial statements, CMPX has consistently generated negative ROIC, with figures reaching -9.6% in 2026Q1, which underscores the company's current inability to compound capital while it remains in the high-cost, pre-commercial phase of developing its bispecific antibody platform for oncology indications.
The persistent decay in ROIC is an expected outcome for a clinical-stage biotech firm where capital is deployed into long-term research rather than revenue-generating assets. This trend warrants further investigation into whether the company can achieve a positive return profile once its lead assets reach the commercialization stage.
According to recent SEC filings, the company's current ratio has fluctuated significantly, dropping from 40.74 in 2024Q1 to 19.04 in 2026Q1, which suggests that while the firm maintains a high nominal liquidity position, the rapid consumption of cash to fund clinical trials is eroding its short-term financial flexibility.
The quick ratio mirrors the current ratio, confirming that the company's liquidity is almost entirely dependent on cash reserves rather than inventory or receivables. This reliance on cash makes the company highly vulnerable to any delays in clinical milestones that would necessitate further dilutive equity financing.
Based on the provided financial data, CMPX maintains a conservative debt-to-equity ratio of 0.05, indicating that management has avoided traditional debt financing in favor of equity-based capital raises to support its ongoing research and development activities throughout the clinical trial process without incurring interest-bearing obligations.
The lack of significant debt is a prudent strategy for a pre-revenue firm, as it avoids the risk of covenant breaches or interest payment defaults. However, this reliance on equity markets means that shareholders bear the full brunt of the company's capital requirements through potential dilution.
Investors frequently misapply net margin and P/E ratios to CMPX, which obscures the company's true operational progress by focusing on accounting losses that are inherent to the clinical-stage biotech business model rather than the underlying clinical trial success and potential future market share of its assets.
These metrics are fundamentally flawed for evaluating a company that has not yet commercialized a product, as they ignore the value of the intellectual property being developed. Analysts should instead focus on cash runway and clinical trial enrollment velocity as more accurate indicators of the company's long-term viability.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CMPX stock.
Compass Therapeutics, Inc.'s current P/E ratio is -5.0x. This places it at the 50th percentile of its historical range.
Compass Therapeutics, Inc.'s return on equity (ROE) is -41.3%. The historical average is -48.8%.
Based on historical data, Compass Therapeutics, Inc. is trading at a P/E of -5.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.